Kongjia Luo, PhD is a Chief Physician in the Department of Thoracic Surgery at Sun Yat-sen University Cancer Center, and serves as a Teaching Coordinator at Sun Yat-sen University School of Medicine. He is a Master’s Supervisor.

His clinical focus is organ-preserving, ultra-minimally invasive treatment for thoracic tumors, spanning the continuum from early detection and risk stratification to precise diagnosis, individualized surgical/endoscopic management, and standardized follow-up. Dr. Luo has extensive experience in the management of pulmonary nodules and lung cancer, esophageal cancer, and complex thoracic conditions such as pleural effusion. Where appropriate, he adopts incision-sparing endoscopic strategies, including natural-orifice endoscopic techniques (NOTES) and other advanced endoscopic therapies, aiming to reduce surgical trauma while maintaining oncologic principles.

In addition to clinical practice, Dr. Luo is dedicated to research on the standardized diagnosis and management of thoracic tumors and precancerous lesions, and the clinical translation of ultra-minimally invasive approaches. He has led and participated in multiple national-level research projects and has published more than 20 SCI-indexed papers as first or corresponding author.

Dr. Luo has received multiple honors, including recognition in the CSCO “35 Under 35” program, and holds a range of academic and professional appointments. He also contributes to interdisciplinary collaboration, including consultation on healthcare applications in medical AI.

· Standardized diagnosis and treatment of thoracic tumors and precancerous lesions.

· Organ-preserving ultra-minimally invasive surgery for thoracic tumors.

· Clinical application of natural orifice transluminal endoscopic surgery (NOTES) in pulmonary nodules, lung cancer and esophageal cancer.

2001.09—2006.06 Sun Yat-sen University School of Clinical Medicine

Clinical Medicine Bachelor of Medicine / Bachelor's Degree

2006.09—2009.06 Sun Yat-sen University Cancer Center

Oncology Master of Philosophy / Master's Degree

2009.09—2012.06 Sun Yat-sen University Cancer Center

Oncology Doctor of Philosophy / Ph.D.

2012.08—2013.12 Sun Yat-sen University Cancer Center

Oncology (Thoracic Surgery) Resident Physician

2014.01—2019.12 Sun Yat-sen University Cancer Center

Oncology (Thoracic Surgery) Attending Physician

2019.12—2024.12 Sun Yat-sen University Cancer Center

Oncology (Thoracic Surgery) Associate Chief Physician

2024.12—Present Sun Yat-sen University Cancer Center

Oncology (Thoracic Surgery) Chief Physician

20+ SCI papers as first/corresponding author in international journals including:

1. Rong Y, Mao LR, Liu YW, Wang WD, Fu XY, Yang H, Wang JY, Yang H, Yang HX, Lin P, Luo KJ. Integrative multi-omics identifies endoplasmic reticulum stress-related prognostic biomarkers and CD99-mediated cell-cell communication in lung adenocarcinoma. Int J Surg. 2026 Feb 1;112(2):4329-4355. doi: 10.1097/JS9.0000000000003888. Epub 2025 Dec 3. PMID: 41342545.

2. Fang CY, Wen J, Wu JD, Li ZC, Huang S, Huang Y, Chen JY, Su HL, Xie XY, Luo KJ, Fu JH, Yang H. Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma. Mol Biomed. 2025 Sep 18;6(1):65. doi: 10.1186/s43556-025-00310-6. PMID: 40963072; PMCID: PMC12443647.

3. Cheng X, Luo K, Gao Y, Wang R, Liu S, Li Q, Zhou S, Yang H, Chen B, Liu Q, Xi M. Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials. Ann Med. 2025 Dec;57(1):2576639. doi: 10.1080/07853890.2025.2576639. Epub 2025 Oct 22. PMID: 41123456; PMCID: PMC12548070.

4. CHEN J Y, YANG H, LIN X D, et al. Diagnostic yield using electromagnetic navigation bronchoscopy for peripheral pulmonary nodules <2 cm[J/OL]. Therapeutic Advances in Respiratory Disease, 2024, 18: 17534666241249150. DOI:10.1177/17534666241249150.

5. Huang Y, Lin X, Fang C, Li Z, Chen J, Xie X, Wu H, Yang H, Luo K, Fu J. Correction: Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study. Cancer Immunol Immunother. 2025 Oct 29;74(11):352. doi: 10.1007/s00262-025-04201-1. Erratum for: Cancer Immunol Immunother. 2025 Sep 11;74(10):303. doi: 10.1007/s00262-025-04168-z. PMID: 41160160; PMCID: PMC12572576.

6. Huang Y, Dong F, Fang C, Wu J, Li Z, Chen J, Xie X, Yang H, Luo K, Fu J. Adjuvant immunotherapy fails to improve survival in ypStage I esophageal cancer after neoadjuvant immunochemotherapy. Cancer Immunol Immunother. 2025 Oct 13;74(11):337. doi: 10.1007/s00262-025-04171-4. PMID: 41081894; PMCID: PMC12518190.

7. Huang Y, Lin X, Fang C, Li Z, Chen J, Xie X, Wu H, Yang H, Luo K, Fu J. Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study. Cancer Immunol Immunother. 2025 Sep 11;74(10):303. doi: 10.1007/s00262-025-04168-z. Erratum in: Cancer Immunol Immunother. 2025 Oct 29;74(11):352. doi: 10.1007/s00262-025-04201-1. PMID: 40931207; PMCID: PMC12423386.